LL-37
Last updated: 1/23/2026 Last reviewed: 1/23/2026
At a Glance
LL-37 is an endogenous human cathelicidin antimicrobial peptide involved in innate immune responses and inflammation, with widely described context-dependent effects. [PMID: 20049649]
⚠️ Research Status: Therapeutic use of LL-37 is experimental. This page is educational and intentionally does not include protocols/dosing.
Mechanism of Action (TBD)
LL-37 has antimicrobial activity and can modulate immune signaling, inflammation, and tissue responses; directionality and net effect can vary by context. [PMID: 20049649]
Evidence Summary
Low Confidence Review 3-10 YearsReview literature describes LL-37 as multifunctional across antimicrobial and immunomodulatory domains. [PMID: 20049649]
Safety & Unknowns
- Translating endogenous-peptide biology into therapy is non-trivial and may carry paradoxical pro- and anti-inflammatory risks.
- Human safety and efficacy depend on formulation, route, and indication, and are not established here.
Regulatory Status
| Region | Status |
|---|---|
| United States (FDA) | Not approved |
| European Union (EMA) | Not approved |
| WADA | Check current list (status may change) |
Changelog
| Date | Change |
|---|---|
| 2026-01-23 | Added dossier and linked primary literature |